Torrent Pharma is taking a bold step forward. In a major move, it’s buying a 46.39% controlling stake in JB Chemicals from New York-based investment firm KKR. That’s not all—Torrent also plans to fully merge with JB Chemicals soon after. This deal, valued at ₹25,689 crore ($3.01 billion), is one of the biggest pharma shakeups in India this year.
The Power Move
Torrent Pharma is known for making strong plays in the Indian market. With this deal, the company clearly wants to go big—both in India and globally. Torrent’s Executive Chairman Samir Mehta said the move will help the company grow its reach and become even stronger in the pharma space.
The deal was announced jointly by Torrent, JB Chemicals, and KKR. Torrent will first pay ₹11,917 crore to buy shares from KKR. After that, it will launch a public offer to buy another 26% from regular shareholders at ₹1,639.18 per share. The company also plans to buy around 2.8% more from JB employees.
Merger on the Cards
Once the share purchases are done, Torrent Pharma and JB Chemicals will merge through a formal scheme. JB shareholders will get 51 Torrent shares for every 100 JB shares they hold. This isn’t just a buyout—it’s a full-blown transformation.
JB Pharma CEO Nikhil Chopra said the companies will be stronger together and better able to improve access to healthcare across markets.
Why This Deal Matters
India is Torrent Pharma’s largest market. It already sells drugs for cancer, infections, and diabetes. Its business is booming—its January–March profits jumped 11% compared to last year.
JB Chemicals also posted strong results recently, boosted by its popular medicines like Metrogyl and Sporlac, which are used to treat stomach issues and hypertension.
Together, the two companies create a powerful force in the industry, especially in chronic care and specialty drugs.
KKR Cashes Out with Big Gains
KKR bought JB Chemicals in 2020 for ₹745 per share. Now, it’s selling its stake at more than double that price. The investment firm made nearly 5x its money back, with a reported internal return of 36%.
That’s a big win for KKR and a bold bet for Torrent Pharma.
Why This Is More Than Just a Deal
This isn’t just another pharma acquisition. It’s a sign that Torrent Pharma wants to lead. Not just compete. And with a smartly executed merger, it might just get there.
Also Read Karnataka Bank Shares Drop 6% After CEO, ED Resign Over Board Differences
